Fast Acting Inhibitor of Gastric Acid Secretion

The method according to claim 8 or 9 wherein said amino acid chelate is a chelate of zinc with an amino acid selected from the group consisting L-cysteine, L-cystine, L-N-acetylcysteine, L-histidine, D-histidine, L-taurine, L-glycinate, L-aspartate and L-methionine.

A method of reducing the likelihood of an ulcer developing in a patient at risk for an ulcer because of elevated acid release in the stomach of said patient comprising administering to said patient at risk an effective amount at least one pharmaceutically acceptable zinc salt.

A method of treating a patient for a disease state or condition selected from the group consisting of gastroesophageal reflux disease, (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE syndrome), ulcer disease and gastric cancer comprising administering to said patient an effective amount of at least one pharmaceutically acceptable zinc salt.

A method of inhibiting vacuolar H+-ATPase, H+, K+-ATPase or both H+-ATPase and H+, K+-ATPase in the stomach of a patient comprising administering to said patient an effective amount of at least one pharmaceutically acceptable zinc salt.

A pharmaceutical composition comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with an effective amount of a proton pump inhibitor, an H2 blocker, an anti-H. pylori agent, a cytoprotective agent, or mixtures thereof, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

A method of treating an H. pylori infection in a patient comprising administering to said patient an effective amount of at least one pharmaceutically acceptable zinc salt, optionally in combination with an anti-H. pylori agent.

Use of an effective amount of at least one pharmaceutically acceptable zinc salt in the manufacture of a medicament for increasing the pH of the gastric juices of the stomach of a patient.

Use of an effective amount of at least one pharmaceutically acceptable zinc salt in the manufacture of a medicament for treating a patient for a disease state or condition selected from the group consisting of gastroesophageal reflux disease, (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE syndrome), ulcer disease and gastric cancer.

Use of at least one pharmaceutically acceptable zinc salt, optionally in combination with an anti-H. pylori agent in the manufacture of a medicament for of treating an H. pylori infection in a patient.

Use of at least one pharmaceutically acceptable zinc salt in the manufacture of a medicament for inhibiting vacuolar H+-ATPase, H+/K+-ATPase or both H+-ATPase and H+/K+-ATPase in the stomach of a patient.

A method of increasing the pH of the gastric juices of the stomach of a patient, said method comprising administering to said patient an effective amount of at least one pharmaceutically acceptable zinc salt selected from the group consisting of zinc acetate, zinc ascorbate, zinc benzoate, zinc bromide, zinc butyrate, zinc caprylate, zinc carbonate, zinc carnosine, zinc citrate, zinc chloride, zinc fluoride, zinc formate, zinc fumarate, zinc gallate, zinc gluconate, zinc glutarate, zinc glycerate, zinc glycerophosphate, zinc glycolate, zinc hydroxide, zinc iodide, zinc lactate, zinc malate, zinc maleate, zinc myristate, zinc nitrate, zinc oxide, zinc phenol sulfonate, zinc phosphate, zinc picolinate, zinc picrate, zinc propionate, zinc salicylate, zinc selenate, zinc succinate, zinc sulfate, zinc tartrate, zinc titanate, zinc undecylenate, zinc valerate, a zinc chelate and mixtures thereof.

A pharmaceutical composition comprising effective amounts at least one water soluble zinc salt in combination with at least one therapeutic agent which is favorably orally administered in combination with salt water soluble zinc salt, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

A method of increasing the bioavailability and/or reducing or alleviating the side effects of an orally administered therapeutic compound comprising coadministering with an effective amount of said compound an amount of at least one water soluble zinc salt effective to enhance the bioavailability and/or reduce or alleviate the side effects of said therapeutic compound.